These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 17374151)
1. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924 [TBL] [Abstract][Full Text] [Related]
6. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L; Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Bayo-Calero JL; Mayordomo JI; Sánchez-Rovira P; Pérez-Carrión R; Illaramendi JJ; García-Bueno JM; González-Flores E; Crespo C; Ramos-Vázquez M; García-Palomo A; Ruiz-Borrego M; de la Haba J; Gómez-Bernal A; Yubero-Esteban A Clin Breast Cancer; 2008 Jun; 8(3):264-8. PubMed ID: 18650157 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Yardley DA; McCleod M; Schreiber F; Murphy P; Patton J; Thompson DS; Shastry M; Rubin M; Melnik M; Burris HA; Hainsworth JD Cancer Invest; 2010 Nov; 28(9):925-31. PubMed ID: 20690806 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400 [TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726 [TBL] [Abstract][Full Text] [Related]
13. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626 [TBL] [Abstract][Full Text] [Related]
14. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007 [TBL] [Abstract][Full Text] [Related]
16. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895 [TBL] [Abstract][Full Text] [Related]
17. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. Tokudome N; Ito Y; Hatake K; Toi M; Sano M; Iwata H; Sato Y; Saeki T; Aogi K; Takashima S Anticancer Drugs; 2008 Aug; 19(7):753-9. PubMed ID: 18594220 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984 [TBL] [Abstract][Full Text] [Related]
20. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]